GlassScriptPhysician profile
Cory Braunstein
NPI 1518795889
$1,273.67
in general payments reported to CMS, 2019-2025
12 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $92.87 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $315.12 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $230.27 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.23 | 2024-2025 | Xifaxan |
| Celltrion USA INC. | $137.15 | 2025 | Zymfentra |
| Genzyme Corporation | $92.35 | 2025 | |
| Ardelyx, INC. | $68.54 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $55.19 | 2025 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $54.40 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $33.66 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $32.92 | 2025 | Rezdiffra |
| Qol Medical, LLC | $25.43 | 2025 | Sucraid |
| Gilead Sciences, INC. | $18.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Braunstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.